Profil
Keith B. Nolop worked as a Senior Director at Schering-Plough Corp.
and as a Vice President-Clinical Research at CoTherix, Inc. He was also the Chief Medical Officer & SVP-Development at Plexxikon, Inc. In 2013-2014, he served as the Chief Medical Officer at Kite Pharma, Inc. Nolop holds a doctorate degree from Vanderbilt University.
Anciens postes connus de Keith B. Nolop
| Sociétés | Poste | Fin |
|---|---|---|
| KITE PHARMA INC | Directeur Technique/Scientifique/R&D | 01/05/2014 |
CoTherix, Inc.
CoTherix, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products | Directeur Technique/Scientifique/R&D | - |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Directeur/Membre du Conseil | 25/05/2010 |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | Directeur Technique/Scientifique/R&D | - |
Formation de Keith B. Nolop
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
CoTherix, Inc.
CoTherix, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products | Health Technology |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | Commercial Services |
Vanderbilt University
Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kite Pharma, Inc.
Kite Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which engages in the development of novel cancer immunotherapeutic products | Health Technology |
















